drugset / Trial / NCT04762602
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Non-randomizedSequentialOpen-labelTreatment
Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
Timeline
- Start
- 2021-02-28
- Primary completion
- 2025-02-27
- Completion
- 2025-02-27
Outcome
Outcome not reported
Stopped (Business): “The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RANOSIDENIB | Small molecule | — | Oral |
Indications
No indication recorded.